A powerful plant-derived toxin with a unique way of killing harmful bacteria has been identified as one of the most promising new antibiotics in decades.
Albicidin, a new antibiotic, is produced by the plant pathogen Xanthomonas albilineans, responsible for causing sugar cane’s destructive leaf scald disease. The toxin is believed to aid the pathogen’s spread by attacking the plant. Albicidin has been shown to be highly effective against harmful bacteria, including drug-resistant superbugs such as E. coli and S. aureus.
Despite its antibiotic potential and low toxicity in pre-clinical experiments, pharmaceutical development of albicidin has been hampered because scientists did not know precisely how it interacted with its target, the bacterial enzyme DNA.
In a study published in the journal Cell Stem Cell on February 2, researchers show that brain organoids—clumps of lab-grown neurons—can integrate with rat brains and respond to visual stimulation like flashing lights.
Decades of research has shown that we can transplant individual human and rodent neurons into rodent brains, and, more recently, it has been demonstrated that human brain organoids can integrate with developing rodent brains. However, whether these organoid grafts can functionally integrate with the visual system of injured adult brains has yet to be explored.
“We focused on not just transplanting individual cells, but actually transplanting tissue,” says senior author H. Isaac Chen, a physician and Assistant Professor of Neurosurgery at the University of Pennsylvania. “Brain organoids have architecture; they have structure that resembles the brain. We were able to look at individual neurons within this structure to gain a deeper understanding of the integration of transplanted organoids.”
SUMMARY Researchers at the George Washington University, together with researchers at the University of California, Los Angeles, and the deep-tech venture startup Optelligence LLC, have developed an optical convolutional neural network accelerator capable of processing large amounts of information, on the order of petabytes, per second. This innovation, which harnesses the massive parallelism of light, heralds a new era of optical signal processing for machine learning with numerous applications, including in self-driving cars, 5G networks, data-centers, biomedical diagnostics, data-security and more.
THE SITUATION Global demand for machine learning hardware is dramatically outpacing current computing power supplies. State-of-the-art electronic hardware, such as graphics processing units and tensor processing unit accelerators, help mitigate this, but are intrinsically challenged by serial data processing that requires iterative data processing and encounters delays from wiring and circuit constraints. Optical alternatives to electronic hardware could help speed up machine learning processes by simplifying the way information is processed in a non-iterative way. However, photonic-based machine learning is typically limited by the number of components that can be placed on photonic integrated circuits, limiting the interconnectivity, while free-space spatial-light-modulators are restricted to slow programming speeds.
THE SOLUTION To achieve a breakthrough in this optical machine learning system, the researchers replaced spatial light modulators with digital mirror-based technology, thus developing a system over 100 times faster. The non-iterative timing of this processor, in combination with rapid programmability and massive parallelization, enables this optical machine learning system to outperform even the top-of-the-line graphics processing units by over one order of magnitude, with room for further optimization beyond the initial prototype.
Check out all the on-demand sessions from the Intelligent Security Summit here.
In recent years, cloud computing has proven itself as one of the fundamental technologies empowering modern enterprises with on-demand connectivity. Without it, the widespread move toward hybrid work wouldn’t have been possible during the COVID–19 pandemic. Yet what about cybersecurity in this new cloud-centric world?
The convenience of instant connectivity has created new vulnerabilities for security teams to confront, and many organizations are still playing catchup, with 81% of organizations experiencing cloud-related security incidents in the past year.
H5N1 avian flu has existed for a quarter century. Only rarely have human cases occurred, with no sustained transmission reported. But “we cannot assume that will remain the case,” WHO Director General Tedros Adhanom Ghebreyesus said at a news conference. New, frequent reports that the disease has crossed into small mammals like minks, otters, foxes, and sea lions are cause for alarm, given the species’ similarities with humans, he noted.
While the risk to people remains low, public health officials must prepare “to face outbreaks in humans, and be ready also to control them as soon as possible,” Dr. Sylvie Briand, director of Global Infectious Hazard Preparedness and Emergency Preparedness at the WHO, told Fortune.
Ghebreyesus cautioned against touching or collecting sick or dead animals, and encouraged those who encounter such to report them to local authorities. Countries must strengthen their avian flu surveillance in areas where humans and wild animals interact, he insisted. And public health officials must work with manufacturers to ensure that vaccines and antivirals are available for global use, he said.
Researchers inserted the gene into the part of the catfish genome that codes for an essential reproductive hormone. The produced hybrids showed increased disease resistance and sterility.
Summary: Advancements in brain mapping and the development of new digital tools over the past decade have opened the door to exciting new discoveries in neuroscience and brain sciences.
Source: University of Oslo.
A billion people worldwide suffer from brain diseases such as dementia, addiction and depression. Scientists carrying out brain research at UiO are now contributing to a more efficient utilization of research data by developing 3D brain atlases and new analytic tools.
Is Director of the Division of Research, Innovation and Ventures (DRIVe — https://drive.hhs.gov/) at the Biomedical Advanced Research and Development Authority (https://aspr.hhs.gov/AboutASPR/ProgramOffices/BARDA/Pages/default.aspx), a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases.
Dr. Patel is committed to advancing high-impact science, building new products, and launching collaborative programs and initiatives with public and private organizations to advance human health and wellness. As the DRIVe Director, Dr. Patel leads a dynamic team built to tackle complex national health security threats by rapidly developing and deploying innovative technologies and approaches that draw from a broad range of disciplines.
Dr. Patel brings extensive experience in public-private partnerships to DRIVe. Prior to joining the DRIVe team, he served as the HHS Open Innovation Manager. In that role, he focused on advancing innovative policy and funding solutions to complex, long-standing problems in healthcare. During his tenure, he successfully built KidneyX, a public-private partnership to spur development of an artificial kidney, helped design and execute the Advancing American Kidney Health Initiative, designed to catalyze innovation, double the number of organs available for transplant, and shift the paradigm of kidney care to be patient-centric and preventative, and included a Presidential Executive Order signed in July 2019. He also created the largest public-facing open innovation program in the U.S. government with more than 190 competitions and $45 million in awards since 2011.
Prior to his tenure at HHS, Dr. Patel co-founded Omusono Labs, a 3D printing and prototyping services company based in Kampala, Uganda; served as a scientific analyst with Discovery Logic, (a Thomson Reuters company) a provider of systems, data, and analytics for real-time portfolio management; and was a Mirzayan Science and Technology Policy Fellow at The National Academies of Science, Engineering, and Medicine. He also served as a scientist at a nanotechnology startup, Kava Technology.
Dr. Renee Wegrzyn, Ph.D. is the inaugural director of the Advanced Research Projects Agency for Health (ARPA-H — https://arpa-h.gov/), an agency that supports the development of high-impact research to drive biomedical and health breakthroughs to deliver transformative, sustainable, and equitable health solutions for everyone. ARPA-H’s mission focuses on leveraging research advances for real world impact.
Previously, Dr. Wegrzyn served as a vice president of business development at Ginkgo Bioworks and head of Innovation at Concentric by Ginkgo, where she focused on applying synthetic biology to outpace infectious diseases—including Covid-19—through biomanufacturing, vaccine innovation and biosurveillance of pathogens at scale.
Prior to Ginkgo, Dr. Wegrzyn was program manager in the Biological Technologies Office at DARPA, where she leveraged the tools of synthetic biology and gene editing to enhance biosecurity, promote public health and support the domestic bioeconomy. Her DARPA portfolio included the Living Foundries: 1,000 Molecules, Safe Genes, Preemptive Expression of Protective Alleles and Response Elements and the Detect it with Gene Editing Technologies programs.
Dr. Wegrzyn received the Superior Public Service Medal for her work and contributions at DARPA. Prior to joining DARPA, she led technical teams in private industry in the areas of biosecurity, gene therapies, emerging infectious disease, neuromodulation, synthetic biology, as well as research and development teams commercializing multiplex immunoassays and peptide-based disease diagnostics.
Students often sacrifice sleep to study for exams, but lack of sleep can negatively impact memory. Now, University of Groningen neuroscientist Robbert Havekes has found that sleep deprivation hinders recall, not retention of information. Havekes and his team used optogenetics and the drug roflumilast to make “hidden knowledge” obtained while sleep-deprived accessible again days later. Their findings were recently published in the journal Current Biology.
Havekes, associate professor of Neuroscience of Memory and Sleep at the University of Groningen, the Netherlands, and his team have extensively studied how sleep deprivation affects memory processes. “We previously focused on finding ways to support memory processes during a sleep deprivation episode”, says Havekes.
However, in his latest study, his team examined whether amnesia as a result of sleep deprivation was a direct result of information loss, or merely caused by difficulties retrieving information.
